. Author manuscript; available in PMC: 2019 Jul 1.

Published in final edited form as: Vascul Pharmacol. 2018 Feb 15;106:37–45. doi: 10.1016/j.vph.2018.02.004

Table 2.

Potency and efficacy of tyramine in renal arteries + and − PVAT in the absence and presence of the NET inhibitor nisoxetine. Points are means±SEM for number of animals indicated on figure 7.

	+PVAT		−PVAT
	−log EC₅₀ [M]	Max	−log EC₅₀ [M]	Max
Vehicle	4.95±0.28	51.6±17.4	2.80±0.30	19.2±8.2
Nisoxetine	3.61±0.23^*	50.7±7.8	3.08±0.32	36.0±10.2

= statistically significant differences (p<0.05) between + and − PVAT variable.